NEW YORK (360Dx) – Oxford Immunotec on Sunday said that its board has approved a share repurchase program of up to $100 million of the company's outstanding ordinary shares over a five-year period.

The program will be presented for shareholder approval on or before the company's annual general shareholder meeting on June 18.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.